Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Vaccine ; 40(46): 6658-6663, 2022 11 02.
Artigo em Inglês | MEDLINE | ID: mdl-36216648

RESUMO

BACKGROUND: People with noncommunicable diseases (NCDs) are at a significantly higher risk of worst outcomes if infected with COVID-19 and thus amongst the main target population for vaccination. Despite prioritizing them for vaccination, the number of vaccinated patients with comorbidities stalled post vaccine introduction. Despite that the government along with partners ran a national awareness campaign to ramp up vaccination coverage, the coverage remained suboptimal. Thus, a one-to-one health counselling initiative was implemented to explore the acceptance of COVID-19 vaccines by the NCDs patients and address the main issues surrounding vaccine hesitancy. This study evaluates the impact of this intervention by analyzing the change in COVID-19 vaccine acceptance. METHODS: In this analytical observational study, a random sample of 57,794 people living with NCDs were approached. Out of them, 12,144 received one-to-one counselling by a group of trained health professionals. The counselled group's vaccine acceptance was assessed on a Likert scale from 1 to 5 pre- and post- counselling. Moreover, a random sample was followed up 2 months after initial counselling to measure their vaccine acceptance and update their vaccination status. RESULTS: 44.5% of total respondents were already registered in the vaccination platform. On a scale from 1 to 5, the overall mean confidence significantly increased by 1.63 from 2.48 pre-counselling to 4.11 post-counselling. Two-months post counselling, a random sample was contacted again and had a mean vaccine confidence of 3.71, which is significantly higher than pre-counselling confidence level despite a significant decrease to post-counselling results. DISCUSSION: Implementing an intervention that targets all key factors impacting health decisions, such as health literacy, risk appraisal and response efficacy, helps reach an adaptive response and increase vaccine confidence. Scholars should be cautious when implementing an intervention since it could lead to maladaptive defensive responses. One-to-one interventions are more effective in population when addressing new interventions and vaccines.


Assuntos
COVID-19 , Doenças não Transmissíveis , Vacinas , Humanos , Vacinas contra COVID-19 , Doenças não Transmissíveis/prevenção & controle , Jordânia , COVID-19/prevenção & controle , Vacinação , Aconselhamento
6.
Pediatr Infect Dis J ; 29(8): 703-6, 2010 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-20308934

RESUMO

BACKGROUND: Moldova experienced a nationwide mumps outbreak between 2007 and 2008. Single-dose monovalent mumps vaccination at 15 to 18 months was introduced in 1983, replaced by a 2-dose MMR schedule at age 1 and 6 to 7 years in 2002. We investigated the outbreak to quantify its extent, explore the role of primary and secondary vaccine failure, and provide control recommendations. METHODS: We analyzed national mumps surveillance and vaccination coverage data to estimate vaccine effectiveness (VE) using the screening method. A retrospective cohort study in 5 educational institutions was conducted to determine age-specific attack rates (ARs) and VE. We compared vaccine strain-specific ARs. Isolation and genotyping of mumps virus strains were performed. RESULTS: Of 31,142 cases reported during October 2007 and July 2008, 80% were in 15- to 24-year-olds. Of cases with information (66%), 92% were vaccinated once, 4% twice. One-dose mumps VE estimates based on surveillance data over 1997-2001 declined from 91% (95% CI: 88%-92%) in 2-year-olds to 72% (70%-74%) in 15- to 19-year-olds. In the cohort study (n = 1589), VE was -40% (-120% to 20%) for 1 dose. For 2 doses it was 62% (-43% to 90%) in 13- to 15-year-olds. ARs were higher in individuals vaccinated with Urabe strains (43%) than with Leningrad-Zagreb strains (14%, P < 0.001). Mumps virus genotype G5 was identified. CONCLUSIONS: Low effectiveness of single-dose mumps vaccination was the main cause of the outbreak. Waning immunity may have contributed to this. The risk of mumps in 2-dose vaccinees was low. Other countries in which large population groups have received <2 doses of mumps vaccine may face similar outbreaks.


Assuntos
Surtos de Doenças , Vírus da Caxumba/isolamento & purificação , Caxumba/epidemiologia , Adolescente , Adulto , Distribuição por Idade , Criança , Pré-Escolar , Estudos de Coortes , Feminino , Humanos , Lactente , Masculino , Moldávia/epidemiologia , Vacina contra Caxumba/administração & dosagem , Vírus da Caxumba/classificação , Vírus da Caxumba/genética , Estudos Retrospectivos , Vacinação/métodos , Vacinação/estatística & dados numéricos , Adulto Jovem
7.
Vaccine ; 26(52): 6980-5, 2008 Dec 09.
Artigo em Inglês | MEDLINE | ID: mdl-18805455

RESUMO

The WHO European Region has a measles elimination target for 2010. Between September 2005 and mid-June 2006, more than 50,000 measles cases were reported in Ukraine; many reportedly had received two doses of measles vaccine and over 60% were among persons 15-29 years old. To investigate vaccine effectiveness (VE), a case-control study was undertaken in Dnepropetrovsk region. VE for two doses of measles vaccine was 93.1%, providing insufficient population immunity for measles elimination. An additional dose of measles vaccine for these age-cohorts is required if Ukraine is to achieve measles elimination. Other republics of the former Soviet Union also need to consider a supplemental dose of measles vaccine for older age groups identified epidemiologically to be at increased risk for measles even though individuals may have already received two doses.


Assuntos
Vacina contra Sarampo/imunologia , Sarampo/epidemiologia , Sarampo/imunologia , Adolescente , Adulto , Estudos de Casos e Controles , Estudos de Coortes , Interpretação Estatística de Dados , Surtos de Doenças , Humanos , Programas de Imunização , Vigilância da População , Tamanho da Amostra , Falha de Tratamento , Ucrânia/epidemiologia , Adulto Jovem
8.
Clin Infect Dis ; 38(12): 1780-3, 2004 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-15227627

RESUMO

To contribute to the development of a rubella vaccination strategy, we conducted a study to determine age-specific susceptibility among women aged 15-39 years by testing for rubella-specific IgG antibodies. Of 964 women, 13% were found to be susceptible to rubella. Significantly higher susceptibility among women >25 years old was observed. Susceptibility data are important but are not sufficient to develop a vaccination strategy. After considering all available information, we suggested vaccination of women aged <35 years and selective vaccination of older women who were planning pregnancy.


Assuntos
Vacina contra Rubéola/administração & dosagem , Rubéola (Sarampo Alemão)/imunologia , Rubéola (Sarampo Alemão)/prevenção & controle , Adolescente , Adulto , Anticorpos Antivirais/sangue , Feminino , Humanos , Imunidade Ativa , Quirguistão , Vírus da Rubéola/imunologia , Vacinação/normas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...